高度致敏肾移植候选者的去列表策略
本综述总结高度致敏肾移植候选者中HLA抗原去列表策略的现行指南、临床结局与脱敏方案。去列表通过将免疫原性较低或抗体风险较低的HLA抗原从不可接受抗原列表中移除,以增加移植机会,但存在预存DSA时移植仍与抗体介导排斥和移植物结局较差相关。由于各中心定义与实施差异大,需多学科团队审慎决策并密切监测。
要点
- 去列表可扩大高度致敏患者移植机会,但预存DSA增加排斥风险。
- 建议阶梯式策略,先针对低风险抗体,再考虑高风险不相容。
- 缺乏标准化定义和统一免疫阈值,需多学科团队参与决策。
核心结论
- 去列表是扩大高度致敏肾移植候选者移植机会的新策略,但预存DSA时移植仍增加抗体介导排斥和移植物结局较差的风险。
研究设计与样本
- 综述,总结现行指南、临床结局和脱敏方案。
主要发现
- 去列表涉及将选定的HLA抗原从不可接受抗原列表中移除,这些抗原被认为免疫原性较低或相应抗体风险较低。
- 当前方法推荐阶梯式策略,初始针对较低风险抗体,当移植否则不太可能时逐步考虑较高风险不相容。
- 预存DSA时移植与抗体介导排斥风险增加和移植物结局较差相关。
关键数值与推荐
- 去列表的定义、资格标准和实施在各中心和国家间差异很大。
- 缺乏标准化定义和统一免疫阈值使决策复杂化。
临床怎么用
- 肾内科医生在多学科团队中应解读复杂免疫信息并参与高度致敏患者的器官分配决策。
- 需仔细选择患者、多学科管理及移植后密切监测。
局限性
- 缺乏标准化定义和统一免疫阈值。
- 各中心和国家间去列表策略的定义、资格标准和实施差异很大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HLA antigen delisting has recently emerged as a new strategy to expand transplant opportunities in the population of broadly sensitised patients who have poor chance to receive a transplant offer through allocation systems due to present donor specific anti-HLA antibodies (DSA). Delisting involves removing selected HLA antigens from the unacceptable antigen list when are considered less immunogenic and/or the corresponding antibodies are considered lower risk, thereby increasing access to transplant offers. Current approaches recommend a stepwise strategy, initially targeting lower-risk antibodies and progressively considering higher-risk incompatibilities when transplantation is otherwise unlikely. However, transplantation in the presence of pre-existing DSA remains associated with increased risk of antibody-mediated rejection and inferior graft outcomes, requiring careful patient selection, multidisciplinary management, and close post-transplant monitoring. As definitions, eligibility criteria, and implementation of delisting strategies differ substantially among centres and countries, nephrologists working within multidisciplinary teams must interpret complex immunological information and participate in organ offer decisions for highly sensitised patients. The absence of standardised definitions and uniform immunological thresholds further complicates decision-making and highlights the need for practical guidance in balancing timely transplantation against long-term graft outcomes. This review provides practical tools for understanding delisting strategies and clinical decision-making by summarising current guidelines, clinical outcomes, and desensitisation protocols to support evidence-based transplantation decisions.
引用
- D'Angelo M, Zahradka I, Jaklova K, et al. Delisting Strategies in Highly Sensitised Kidney Transplant Candidates. Nephrol Dial Transplant. 2026. PMID: 42836549. doi:10.1093/ndt/gfag229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。